Lupus & antiphospholipid syndrome
Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study
Authors' conclusion
Concomitant SLE does not appear to modify long-term recurrent thrombosis risk, or aPL phenotypes, in patients with APS.
Study context
- Population
- Patients with thrombotic antiphospholipid syndrome (APS), with systemic lupus erythematosus (SLE)-associated APS (SLE-APS) or primary APS (PAPS); single centre
- Participants
- 118 patients
- Exposure
- SLE-associated APS vs primary APS
- SLE-APSn = 58
- PAPSn = 60reference
- Outcome
- Thrombotic phenotype
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Microvascular thrombosis, SLE-APS vs PAPS
12.1% vs 0%
Mixed thrombotic phenotype, SLE-APS vs PAPS (p = 0.05)
19.0% vs 6.7%
Recurrent thrombosis incidence rates and Kaplan-Meier recurrence-free survival after index thrombosis similar
∼0.5 events/10-patient years
Observational data: associations, not effects.
Further findings
Median follow-up
Age at APS diagnosis · lower in SLE-APS
P < 0.05
aPL subtype distribution
- Similar across cohorts
Triple-aPL-positivity vs not, PAPS cohort only
- Recurrent thrombosis event rate, incidence rate ratio 2.22
- P = 0.03
- Lower recurrence-free survival after first thrombosis
- log-rank test p = 0.01
Lupus anticoagulant (LA)-positivity vs LA-negativity, PAPS cohort only
- Arterial thrombosis, RR 2.69
- P = 0.01
- Venous thromboembolism (VTE), RR 0.48
- P < 0.001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →